Your browser doesn't support javascript.
loading
P3 cap modified Phe*-Ala series BACE inhibitors.
Chen, Shu-Hui; Lamar, Jason; Guo, Deqi; Kohn, Todd; Yang, Hsiu-Chiung; McGee, James; Timm, David; Erickson, Jon; Yip, Yvonne; May, Patrick; McCarthy, James.
Afiliação
  • Chen SH; Lilly Research Laboratories, Discovery Chemistry Division and Technology, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. chen_shu-hui@lilly.com
Bioorg Med Chem Lett ; 14(1): 245-50, 2004 Jan 05.
Article em En | MEDLINE | ID: mdl-14684336
ABSTRACT
With the aim of reducing molecular weight and adjusting log D value of BACE inhibitors to more favorable range for BBB penetration and better bioavailability, we synthesized and evaluated several series of P3 cap modified BACE inhibitors obtained via replacement of the P3NHBoc moiety as seen in 3 with other polar functional groups such as amino, hydroxyl and fluorine. Several promising inhibitors emerging from this P3 cap SAR study (e.g., 15 and 19) demonstrated good enzyme inhibitory potencies (BACE-1 IC(50) <50 nM) and whole cell activities (IC(50) approximately 1 microM).
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Endopeptidases / Inibidores de Proteases / Dipeptídeos Limite: Humans Idioma: En Ano de publicação: 2004 Tipo de documento: Article
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Endopeptidases / Inibidores de Proteases / Dipeptídeos Limite: Humans Idioma: En Ano de publicação: 2004 Tipo de documento: Article